Galecto welcomes Dr. Anne Prener to its Board of Directors

– DENMARK, Copenhagen –  Galecto, Inc., (NASDAQ: GLTO) a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors.

“We warmly welcome Anne to our Board. She will be a tremendous asset with her deep experience and exceptional leadership qualities,” said CEO, Hans Schambye. “Anne brings to our Board a unique perspective after having served as CEO on several companies; she is an accomplished and seasoned executive, and we welcome her guidance.”

About Dr. Anne Prener

Dr. Anne Prener has more than 25 years of leadership experience within life sciences companies and currently serves as CEO of Imbria Inc. and as a venture partner at SV Health Investors. Dr. Prener previously served as CEO of Freeline Ltd. Dr. Prener has led companies and teams across several therapeutic areas, including a focus on rare diseases. As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from the preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development, and a commercial-scale, high-quality CMC and manufacturing platform. Before joining Freeline, she served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases. Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and VP, Clinical Research Hematology at Baxalta. During her time there, three new major product approvals in the U.S. and EU were secured along with significant advancement in Baxalta’s hematology portfolio. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as SVP, Hemophilia R&D Portfolio, where she was instrumental in building a portfolio of late-stage and commercial hemophilia products.

Dr. Prener serves on the Boards of Directors of several life science companies, Rubius Therapeutics, Kaleido Bioscience, and Renovacor.

Dr. Anne Prener commented, “I am delighted to join this dynamic company’s Board of Directors. Galecto has an exciting pipeline of product candidates within fibrosis and cancer and a lead candidate in phase 2 for Idiopathic pulmonary fibrosis. After reviewing the accomplishments and the opportunities that lie ahead, I believe in management’s vision and opportunity to make a meaningful difference in the lives of patients suffering from IPF.”

Dr. Prener holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.

About Galecto

Galecto is a clinical-stage biotechnology company incorporated in the U.S. with advanced programs in fibrosis and cancer centered on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. The company’s pipeline includes our lead product candidate, which is an inhaled galectin-3 modulator currently in phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Our pipeline also includes two additional assets to move into phase 2 studies.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team